Eli Lilly (LLY)
(Delayed Data from NYSE)
$787.02 USD
+23.04 (3.02%)
Updated May 15, 2024 04:00 PM ET
After-Market: $786.99 -0.03 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Brokerage Reports
Eli Lilly and Company [LLY]
Reports for Purchase
Showing records 41 - 60 ( 426 total )
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 81123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 8123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 72123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 71123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended June 30.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended June 2.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended April 7.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 41123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 4123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Biotechnology- Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 24.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 32123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 31123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 3123
Provider: Stock Traders Daily
Analyst: Research Department